Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients.

Jernström H, Bågeman E, Rose C, Jönsson PE, Ingvar C.

Br J Cancer. 2009 Dec 1;101(11):1817-23. doi: 10.1038/sj.bjc.6605428.

2.

Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status.

Simonsson M, Söderlind V, Henningson M, Hjertberg M, Rose C, Ingvar C, Jernström H.

Cancer Causes Control. 2013 May;24(5):929-40. doi: 10.1007/s10552-013-0169-1. Epub 2013 Feb 15.

PMID:
23412805
3.

No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.

Markkula A, Hjertberg M, Rose C, Ingvar C, Jernström H.

Acta Oncol. 2014 Feb;53(2):195-200. doi: 10.3109/0284186X.2013.840739. Epub 2013 Oct 14.

PMID:
24125101
4.

Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms.

Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U, Rane A.

Biochem Biophys Res Commun. 2002 Nov 22;299(1):25-8.

PMID:
12435384
5.

Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.

García-Martín E, Martínez C, Tabarés B, Frías J, Agúndez JA.

Clin Pharmacol Ther. 2004 Aug;76(2):119-27.

PMID:
15289789
6.

Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer.

Alcazar-González GA, Calderón-Garcidueñas AL, Garza-Rodríguez ML, Rubio-Hernández G, Escorza-Treviño S, Olano-Martin E, Cerda-Flores RM, Castruita-Avila AL, González-Guerrero JF, le Brun S, Simon-Buela L, Barrera-Saldaña HA.

Pharmacogenomics. 2013 Oct;14(13):1583-92. doi: 10.2217/pgs.13.83.

PMID:
24088129
7.

CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.

Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, Dees EC.

Breast Cancer Res Treat. 2012 Jul;134(1):401-10. doi: 10.1007/s10549-012-2054-0. Epub 2012 Apr 18.

8.

Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.

Kok M, Koornstra RH, Mook S, Hauptmann M, Fles R, Jansen MP, Berns EM, Linn SC, Van 't Veer LJ.

Breast. 2012 Dec;21(6):769-78. doi: 10.1016/j.breast.2012.04.010. Epub 2012 Jun 26.

PMID:
22738860
9.

Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.

Park IH, Ro J, Park S, Lim HS, Lee KS, Kang HS, Jung SY, Lee S.

Breast Cancer Res Treat. 2012 Jan;131(2):455-61. doi: 10.1007/s10549-011-1425-2. Epub 2011 Mar 25.

PMID:
21437611
10.

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.

Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P.

J Clin Oncol. 2005 Aug 1;23(22):5138-47. Epub 2005 Jul 11.

PMID:
16009955
11.

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.

Wegman P, Elingarami S, Carstensen J, Stål O, Nordenskjöld B, Wingren S.

Breast Cancer Res. 2007;9(1):R7.

12.

Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.

International Breast Cancer Study Group, Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD.

J Clin Oncol. 2006 Mar 20;24(9):1332-41. Epub 2006 Feb 27.

PMID:
16505417
13.

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA.

J Natl Cancer Inst. 2005 Jan 5;97(1):30-9.

PMID:
15632378
14.

Clinical effects of A4889G and T6235C polymorphisms in cytochrome P-450 CYP1A1 for breast cancer patients treated with tamoxifen: implications for tumor aggressiveness and patient survival.

Cardoso-Filho C, Sarian LO, de Oliveira CB, da Silveira Bossi L, Lourenço GJ, Lima CS, Gurgel MS.

Cancer Chemother Pharmacol. 2013 Sep;72(3):529-35. doi: 10.1007/s00280-013-2221-y. Epub 2013 Jul 11.

PMID:
23842721
15.

Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.

Dezentjé VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP, Casparie MK, Egberts AC, Nortier JW, Guchelaar HJ.

J Clin Oncol. 2010 May 10;28(14):2423-9. doi: 10.1200/JCO.2009.25.0894. Epub 2010 Apr 12.

PMID:
20385997
16.

Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.

Bartlett JM, Thomas J, Ross DT, Seitz RS, Ring BZ, Beck RA, Pedersen HC, Munro A, Kunkler IH, Campbell FM, Jack W, Kerr GR, Johnstone L, Cameron DA, Chetty U.

Breast Cancer Res. 2010;12(4):R47. doi: 10.1186/bcr2604. Epub 2010 Jul 8.

17.

Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.

Leskelä S, Jara C, Leandro-García LJ, Martínez A, García-Donas J, Hernando S, Hurtado A, Vicario JC, Montero-Conde C, Landa I, López-Jiménez E, Cascón A, Milne RL, Robledo M, Rodríguez-Antona C.

Pharmacogenomics J. 2011 Apr;11(2):121-9. doi: 10.1038/tpj.2010.13. Epub 2010 Mar 9.

PMID:
20212519
19.
20.

Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.

Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, Paridaens R; European Organisation for Research and Treatment of Cancer Breast Group; Scottish Breast Cancer Trials Group.

Eur J Cancer. 2007 Jan;43(2):331-40. Epub 2006 Nov 28.

PMID:
17134892

Supplemental Content

Support Center